Ident. | Authors (with country if any) | Title |
---|
000002 |
Magda Osman [Royaume-Uni] ; Agata Rytersk [Royaume-Uni] ; Kash Karimi [Royaume-Uni] ; LINGLING TU [République populaire de Chine] ; Ignacio Obeso [Canada] ; Maarten Speekenbrink [Royaume-Uni] ; Marjan Jahanshahi [Royaume-Uni] | The effects of dopaminergic medication on dynamic decision making in Parkinson's disease |
000005 |
Michel Panisset [Canada] ; Jack J. Chen [États-Unis] ; Sean H. Rhyee [États-Unis] ; Jill Conner [États-Unis] ; Julie Mathena [États-Unis] | Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO) |
000006 |
Santiago Perez-Lloret [France] ; María Ver Nica Rey [France] ; James Crispo [Canada] ; Daniel Krewski [Canada] ; Marise Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France] | Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients |
000044 |
James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
000085 |
Kaylena A. Ehgoetz Martens [Canada] ; Colin G. Ellard [Canada] ; Quincy J. Almeida [Canada] | Dopaminergic contributions to distance estimation in Parkinson's disease: A sensory-perceptual deficit? |
000087 |
Jolyn N. A. D'Andrea [Canada] ; Angela M. Haffenden [Canada] ; Sarah Furtado [Canada] ; Oksana Suchowersky [Canada] ; Bradley G. Goodyear [Canada] | Degradation of stored movement representations in the parkinsonian brain and the impact of levodopa |
000094 |
Mee-Sook Song [Canada] ; Dmitriy Matveychuk [Canada] ; Erin M. Mackenzie [Canada] ; Maryana Duchcherer [Canada] ; Darrell D. Mousseau [Canada] ; Glen B. Baker [Canada] | An update on amine oxidase inhibitors: Multifaceted drugs |
000101 |
Dominic Nadeau [Canada] ; Isabelle Giroux [Canada] ; Julie Dufour [Canada] ; Martine Simard [Canada] | Jeu pathologique chez les patients atteints de la maladie de Parkinson |
000293 |
A. Q. Rana [Canada] ; J. Depradine [Canada] | Abdominal Pain: A Symptom of Levodopa End of Dose Wearing off in Parkinson's Disease |
000308 |
Marc Morissette [Canada] ; Pershia Samadi [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Nancy Belanger [Canada] ; Thérèse Di Paolo [Canada] | Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys |
000360 |
Sarah C. Lidstone [Canada] ; Michael Schulzer [Canada] ; Katherine Dinelle [Canada] ; Edwin Mak [Canada] ; Vesna Sossi [Canada] ; Thomas J. Ruth [Canada] ; Raul De La Fuente-Fernandez [Canada] ; Anthony G. Phillips [Canada] ; A. Jon Stoessl [Canada] | Effects of Expectation on Placebo-Induced Dopamine Release in Parkinson Disease |
000432 |
Pierre-Luc Tremblay [Canada] ; Marc-Andre Bedard [Canada] ; Maxime Levesque [Canada] ; Mark Chebli [Canada] ; Maxime Parent [Canada] ; Richard Courtemanche [Canada] ; Pierre J. Blanchet [Canada] | Motor sequence learning in primate : Role of the D2 receptor in movement chunking during consolidation |
000498 |
C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Robert Hauser [États-Unis] ; Paul D. Feigin [Israël] ; Joseph Jankovic [États-Unis] ; Anthony Lang [Canada] ; William Langston [États-Unis] ; Eldad Melamed [Israël] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne] | A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease |
000500 |
Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [États-Unis] ; Pershia Samadi [Canada] ; Paul J. Bedard [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Therese Di Paolo [Canada] | Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys |
000713 |
Jon Doan [Canada] ; Ian Q. Whishaw [Canada] ; Sergio M. Pellis [Canada] ; Oksana Suchowersky [Canada] ; Lesley A. Brown [Canada] | Motor deficits in parkinsonian reaching : Dopa-sensitivity influenced by real-world task constraint |
000773 |
ZHIGANG HONG [États-Unis] ; Andrew J. Smith [États-Unis] ; Stephen L. Archer [Canada] ; Xi-Chen Wu [Canada] ; Daniel P. Nelson [États-Unis] ; Douglas Peterson [États-Unis] ; Gerhard Johnson [États-Unis] ; E. Kenneth Weir [États-Unis] | Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction |
000776 |
Kyle G. Melvin [Canada] ; Jon Doan [Canada] ; Sergio M. Pellis [Canada] ; Lesley Brown [Canada] ; Ian Q. Whishaw [Canada] ; Oksana Suchowersky [Canada] | Pallidal deep brain stimulation and L-dopa do not improve qualitative aspects of skilled reaching in parkinson's disease |
000789 |
Anthony O'Hagan [Royaume-Uni] ; Christopher Mccabe [Royaume-Uni] ; Ron Akehurst [Royaume-Uni] ; Alan Brennan [Royaume-Uni] ; Andrew Briggs [Royaume-Uni] ; Karl Claxton [Royaume-Uni] ; Elisabeth Fenwick [Royaume-Uni] ; Dennis Fryback [États-Unis] ; Mark Sculpher [Royaume-Uni] ; David Spiegelhalter [Royaume-Uni] ; Andrew Willan [Canada] | Incorporation of uncertainty in health economic modelling studies |
000871 |
Erwan Bezard [France] ; Michael P. Hill [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Anne Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque |
000884 |
Naila Ismayilova [Canada] ; Alan Crossman [Canada] ; Alexei Verkhratsky [Canada] ; Jonathan Brotchie [Canada] | Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats |
000908 |
W. R. Wayne Martin [Canada] ; Marguerite Wieler [Canada] | Treatment of Parkinson's disease |
000910 |
Pierre J. Blanchet [Canada] | The fluctuating Parkinsonian patient: Clinical and pathophysiological aspects |
000920 |
Pierre J. Blanchet [États-Unis, Canada] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] | Renaissance of amantadine in the treatment of Parkinson's disease |
000934 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
000937 |
A. Hadj Tahar [Canada] ; R. Grondin [Canada] ; L. Gregoire [Canada] ; F. Calon [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable |
000965 |
Michael Iskedjian [Canada] ; Thomas R. Einarson [Canada] | Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease |
000967 |
Mahyar Etminan [Canada] ; Sudeep Gill [Canada] ; Ali Samii [États-Unis] | Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis |
000971 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications |
000A29 |
C. E. Clarke [Royaume-Uni] ; M. Guttman [Canada] | Dopamine agonist monotherapy in Parkinson's disease |
000A37 |
Nicole Duchesne [Canada] ; Jean-Paul Soucy [Canada] ; Hélène Masson [Canada] ; Sylvain Chouinard [Canada] ; Marc-André Bedard [Canada] | Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: A single photon emission computed tomography study using 123Iodine-β-CIT in patients on and OFF levodopa |
000A38 |
Azi H. Rajput [Canada] ; Mark E. Fenton [Canada] ; Sam Birdi [Canada] ; Rob Macaulay [Canada] ; David George [Canada] ; Bohdar Rozdilsky [Canada] ; Lee C. Ang [Canada] ; Ambikaipakan Senthilselvan [Canada] ; Oleh Hornykiewicz [Autriche] | Clinical-pathological study of levodopa complications |
000A50 |
Wakako Maruyama [Japon] ; Yukihiro Akao [Japon] ; Moussa B. H. Youdim [Israël] ; Bruce A. Davis [Canada] ; Makoto Naoi [Japon] | Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol |
000A66 |
Erik Ch. Wolters [Pays-Bas] | Psychiatric complications in the treatment of Parkinson's disease |
000A78 |
Doris J. Doudet [Canada] | Monitoring disease progression in Parkinson's disease |
000A80 |
Richard Camicioli [États-Unis, Canada] ; Eric Lea [États-Unis] ; John G. Nutt [États-Unis] ; Gary Sexton [États-Unis] ; Barry S. Oken [États-Unis] | Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study |
000A84 |
Ron Levy [Canada] ; Anthony E. Lang [Canada] ; Jonathan O. Dostrovsky [Canada] ; Peter Pahapill [États-Unis] ; John Romas [Canada] ; Jean Saint-Cyr [Canada] ; William D. Hutchison [Canada] ; Andres M. Lozano [Canada] | Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms |
000A89 |
Mahyar Etminan [Canada] ; Ali Samii [États-Unis] ; Bahi Takkouche [Espagne] ; Paula A. Rochon [Canada] | Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials |
000B03 |
John G. Nutt [États-Unis] | Fluctuations in response to treatment for Parkinson's disease |
000B13 |
ABDALLAH HADJ TAHAR [Canada] ; Anna Ekesbo [Suède] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Kjell A. Svensson [États-Unis] ; Joakim Tedroff [Suède] ; Paul J. Bedard [Canada] | Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys |
000B26 |
Oksana Suchowersky [États-Unis, Canada] ; Peter Bailey ; E. Pourcher ; Lynne Bulger ; Giovanni Facciponte | Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD |
000B33 |
Marco Scarselli [Italie] ; Marianna Armogida [Italie] ; Carla Pardini [Italie] ; Serena Chiacchio [Italie] ; Giovanni U. Corsini [Italie] | Apomorphine: A novel effect for an old compound |
000B46 |
D. J. Chong [Canada] ; O. Suchowersky [Canada] ; C. Szumlanski [États-Unis] ; R. M. Weinshilboum [États-Unis] ; R. Brant [Canada] ; N. R. C. Campbell [Canada] | The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's Disease |
000B53 |
ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada] | Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys |
000B54 |
A. E. Lang [Canada] ; LANGSTON ; RASCOL ; BROTCHIE ; BENABID ; MELAMED ; BONUCELLI ; OLANOW ; OBESO ; GIMENEZ-ROLDAN ; RAJPUT ; FAHN ; NUTT ; BROOKS ; CHASE | Surgery for levodopa-induced dyskinesias. Discussion |
000B58 |
Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique] | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial |
000B60 |
M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys |
000B63 |
Andis Klegeris [Canada] ; Patrick L. Mcgeer [Canada] | R-(-)-deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition |
000B65 |
M. Filion [Canada] ; OBESO ; BENABID ; OLANOW ; LANG ; HIRSCH ; NUTT | Physiologic basis of dyskinesia. Discussion |
000B81 |
F. Calon [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; P. J. Blanchet [Canada] ; T. T. Di Paolo [Canada] ; P. J. Bedard [Canada] | Molecular basis of levodopa-induced dyskinesias |
000B94 |
C. S. Lee [Canada] ; M. A. Cenci [Suède] ; M. Schulzer [Canada] ; A. Björklund [Suède] | Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease |
000B95 |
J. M. Van Kampen [Canada] ; A. J. Stoessl [Canada] | Effects of oligonucleotide antisense to dopamine D1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia |
000C06 |
T. J. Hudzik [États-Unis] ; A. Howell [États-Unis] ; K. Payza [Canada] ; A. J. Cross [États-Unis] | Antiparkinson potential of δ-opioid receptor agonists |
000C07 |
ABDALLAH HADJ TAHAR [Canada] ; N. Belanger [Canada] ; E. Bangassoro [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys |
000C12 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada] | A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa |
000C19 |
D. A. Grimes [Canada] ; A. E. Lang | Treatment of early Parkinson's disease |
000C24 |
Juan Fernandez-Ruiz [États-Unis] ; Doris Doudet [Canada] ; Thomas G. Aigner [États-Unis] | Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys |
000C28 |
D. E. Hobson [Canada] ; E. Pourcher [Canada] ; W. R. W. Martin [Canada] | Ropinirole and pramipexole, the new agonists |
000C31 |
P. J. Blanchet [Canada] | Rationale for use of dopamine agonists in Parkinson's disease : Review of ergot derivatives |
000C37 |
K. Kitani [Japon] ; S. Kanai [Japon] ; G. O. Ivy [Canada] ; M. C. Carrillo [Argentine] | Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl : a possible antioxidant strategy |
000C39 |
D. B. King [Canada] | Parkinson's disease : Levodopa complications |
000C45 |
D. L. Gelowitz [États-Unis] ; I. A. Paterson [Canada] | Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration |
000C47 |
T. Mendis [Canada] ; O. Suchowersky [Canada] ; A. Lang [Canada] ; S. Gauthier [Canada] | Management of Parkinson's disease : A review of current and new therapies |
000C60 |
V. D. Doan [Canada] ; R. Grondin [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys |
000C62 |
R. Grondin [Canada] ; M. Goulet [Canada] ; M. Morissette [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958 |
000C64 |
E. M. Khalil [États-Unis] ; W. H. Ojala [États-Unis] ; A. Pradhan [Canada] ; V. D. Nair [Canada] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis] | Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide |
000C65 |
R. Grondin [Canada] ; V. D. Doan ; L. Gregoire ; P. J. Bedard | D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys |
000C73 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; A. Hadj Tahar [Canada] ; L. Gregoire [Canada] ; A. Mori [Japon] ; H. Kase [Japon] | Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys |
000C77 |
T. L. Sourkes [Canada] | "Rational hope" in the early treatment of Parkinson's disease |
000C81 |
A. H. Rajput [Canada] ; W. Martin [Canada] ; M.-H. Saint-Hilaire [États-Unis] ; E. Dorflinger [États-Unis] ; S. Pedder [États-Unis] | Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon : A double-blind, placebo-controlled, multicenter trial |
000C90 |
A. Samii [Canada] ; S. R. Letwin [Canada] ; D. B. Calne [Canada] | Prospects for new drug treatment in idiopathic parkinsonism |
000C99 |
V. P. Calabrese [Canada] ; K. A. Lloyd [Canada] ; P. Brancazio [Canada] ; E. Cefali [États-Unis] ; P. Martin [États-Unis] ; J. Jr Wall [États-Unis] ; D. Sica [États-Unis] | N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism |
000D05 |
J. H. Growdon [États-Unis] ; K. Kieburtz [Canada] ; M. P. Mcdermott [Canada] ; M. Panisset [Canada] ; J. H. Friedman [États-Unis] | Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients |
000D28 |
D. A. Loeffler [États-Unis] ; P. A. Lewitt [États-Unis] ; P. L. Juneau [États-Unis] ; D. M. Camp [États-Unis] ; A. J. Demaggio [États-Unis] ; P. Milbury [États-Unis] ; W. R. Matson [États-Unis] ; M. P. Rathbone [Canada] | Altered guanosine and guanine concentrations in rabbit striatum following increased dopamine turnover |
000D45 |
A. Destee [France] | Données séméiologiques et principes actuels du traitement médical |
000D50 |
A. H. Rajput [Canada] ; W. Martin [Canada] ; M.-H. Saint-Hilaire [États-Unis] ; E. Dorflinger [États-Unis] ; S. Pedder [États-Unis] | Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial |
000D53 |
I. H. Richard [États-Unis] ; R. Kurlan [États-Unis] ; C. Tanner [États-Unis] ; S. Factor [États-Unis] ; J. Hubble [États-Unis] ; O. Suchowersky [Canada] ; C. Waters [États-Unis] | Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease |
000D60 |
C.-T. Lai [Canada] ; P. H. Yu [Canada] | R(-)-deprenyl potentiates dopamine induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells |
000D62 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; D. R. Britton [États-Unis] ; K. Shiosaki [États-Unis] | Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929 : An acute study in parkinsonian levodopa-primed monkeys |
000D64 |
S. Rohatagi [États-Unis] ; J. S. Barrett [États-Unis] ; K. E. Dewitt [États-Unis] ; D. Lessard [Canada] ; R. J. Morales [États-Unis] | Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system |
000D85 |
D. J. Doudet [Canada] ; G. L. Y. Chan [Canada] ; J. E. Holden [États-Unis] ; K. S. Morrison [Canada] ; R. J. Wyatt [États-Unis] ; T. J. Ruth [Canada] | Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced Parkinsonism in monkeys |
000D90 |
M. Guttman [Canada] | Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease |
000D91 |
C.-T. Lai [Canada] ; P. H. Yu [Canada] | Dopamine- and L-β-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells : effects of oxidative stress and antioxidative factors |
000D92 |
A. Rajput [États-Unis] ; A. Kishore [Canada] ; B. Snow [Canada] ; C. F. Bolton [Canada] ; A. H. Rajput [Canada] | Dopa-responsive, nonprogressive, juvenile parkinsonism : Report of a case |
000E00 |
R. Kakkar [Canada] ; R. V. S. Raju [Canada] ; A. H. Rajput [Canada] ; R. K. Sharma [Canada] | Amantadine: an antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme |
000E11 |
P. J. Blanchet [Canada] ; P. Allard [Canada] ; L. Gregoire [Canada] ; F. Tardif [Canada] ; P. J. Bedard [Canada] | Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients |
000E13 |
P. Sandor [Canada] ; A. E. Lang [Canada] ; S. Singal [Canada] ; C. Augus [Canada] | Remoxipride in the treatment of levodopa-induced psychosis |
000E16 |
W. G. Tatton [Canada] ; R. M. E. Chalmers-Redman [Canada] | Modulation of gene expression rather than monoamine oxidase inhibition : (-)-Deprenyl-related compounds in controlling neurodegeneration |
000E22 |
J.-J. Soghomonian [Canada] ; S. Pedneault [Canada] ; P. J. Blanchet [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | L-DOPA regulates glutamate decarboxylases mRNA levels in MPTP-treated monkeys |
000E29 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
000E31 |
P. J. Blanchet [Canada] ; R. Grondin [Canada] ; P. J. Bedard [Canada] ; K. Shiosaki [États-Unis] ; D. R. Britton [États-Unis] | Dopamine D1 receptor desensitization profile in MPTP-lesioned primates |
000E36 |
R. Grondin [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates |
000E50 |
A. E. Lang [Canada] ; P. Sandor ; J. Duff [Canada] | Remoxipride in Parkinson's disease : differential response in patients with dyskinesias fluctuations versus psychosis |
000E60 |
P. J. Blanchet ; B. Gomez-Mancilla [Canada] ; T. Di Paolo ; P. J. Bedard | Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia ? |
000E66 |
C. Gagnon [Canada] ; B. Gomez-Mancilla ; R. Markstein ; P. J. Bedard ; T. Di Paolo [Canada] | Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys : regional changes of brain dopamine receptors |
000E69 |
P. J. Bedard [Canada] ; B. Gomez-Mancilla [Canada] ; P. Blanchet [Canada] ; R. Grondin [Canada] ; T. Dipaolo [Canada] ; SETHY ; PIERCEY ; CHASE ; WISE ; PERLMUTTER ; RANHOSKY | Dopamine-receptor families and the treatment of Parkinson's disease. Discussion |
000E72 |
P. J. Bedard [Canada] | D-1 receptor in neurology and psychiatry : an overview : The role of D-1 dopamine receptors in neurology and psychiatry |
000E88 |
E. Scarr [Canada] ; D. M. Wingerchuk ; A. V. Juorio ; I. A. Paterson | The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions |
000F10 |
P. J. Blanchet [Canada] ; R. Boucher [Canada] ; P. J. Bedard | Excitotoxic lateral pallidotomy does not relieve L-DOPA-induced dyskinesia in MPTP parkinsonian monkeys |
000F36 |
M. Takada [Canada] ; T. Sugimoto ; T. Hattori [Canada] | MPTP neurotoxicity to cerebellar Purkinje cells in mice |
000F44 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
000F45 |
P. Blanchet [Canada] ; P. J. Bedard [Canada] ; D. R. Britton ; J. W. Kebabian | Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys |
000F57 |
M. Guttman [Canada] ; G. Leger ; A. Reches ; A. Evans ; H. Kuwabara ; J. M. Cedarbaum ; A. Gjedde | Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa |
000F61 |
| 3 rd Canadian conference on neurodegenerative diseases, L'Estérel PQ, April 4-6, 1991 |
000F68 |
M. Schulzer [Canada] ; E. Mark ; D. B. Calne | The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic |
000F70 |
H. A. Robertson [Canada] ; M. R. Peterson ; G. G. Worth | Synergistic and persistent interaction between the D2 agonist, bromocriptine, and the D1 selective agonist, CY 208-243 |
000F88 |
E. Pourcher [Canada] ; B. Gomez-Mancilla ; P. J. Bedard | Ethosuximide and tremor in Parkinson's disease : a pilot study |
000F91 |
B. Gomez-Mancilla [Canada] ; P. J. Bedard | Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys |
000F92 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
001015 |
W. G. Tatton [Canada] ; C. E. Greenwood | Rescue of dying neurons : a new action for deprenyl in MPTP parkinsonism |
001030 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism |
001031 |
B. Gomez-Mancilla [Canada] ; P. J. Bedard | Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys |
001032 |
O. S. Kofman [Canada] | Deprenyl : protective vs. symptomatic effect |
001037 |
F. B. Jolicoeur ; R. Rivest ; S. St.-Pierre ; A. Drumheller | Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats |
001048 |
N. R. C. Campbell ; D. Rankine ; A. E. Goodridge ; B. B. Hasinoff ; M. Kara | Sinemet-ferrous sulphate interaction in patients with Parkinson's disease |
001063 |
C. Rouillard ; P. J. Bedard ; T. Di Paolo | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393 |
001070 |
J. K. C. Tsui ; R. F. Peppard ; K. C. Petruk ; G. Allen ; R. S. Burns ; D. B. Calne | Decreased efficay of levodopa with carbidopa in parkinsonian patients after adrenal-to-caudate implants |
001074 |
E. C. Wolters ; T. A. Hurwitz ; E. Mak ; P. Teal ; F. R. Peppard ; R. Remick ; S. Calne ; D. B. Calne | Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis |
001082 |
J. K. Tsui ; S. Ross ; K. Poulin ; J. Douglas ; D. Postnikoff ; S. Calne ; W. Woodward ; D. B. Calne | The effect of dietary protein on the efficacy of L-dopa: a double-blind study |
001084 |
W. G. Vincken ; C. M. Darauay ; M. G. Cosio | Reversibility of upper airway obstruction after levodopa therapy in Parkinson's disease |
001117 |
D. Riley ; A. E. Lang | Practical application of a low-protein diet for Parkinson's disease |
001130 |
E. C. Wolters ; J. C. Kebabian ; M. Guttman ; E. Mak ; B. D. Pate ; D. B. Calne | A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys |
001138 |
J. A. Sharpe ; W. A. Fletcher ; A. E. Lang ; D. H. Zackon | Smooth pursuit during dose-related on-off fluctuations in Parkinson's disease |
001146 |
A. E. Lang | Manipulating the dopaminergic system in Parkinson's disease |
001147 |
H. A. Robertson ; G. S. Robertson | Hypothesis. Combined L-dopa and bromocriptine therapy for Parkinson's disease: a proposed mechanism of action |
001159 |
I. Libman ; M. J. Gawel ; R. J. Riopelle ; S. Bouchard | A comparison of bromocriptine (Parlodel®) and levodopa-carbidopa (Sinemet®) for treatment of "De Novö Parkinson's disease patients |
001167 |
C. B. Bozek ; O. Suchowersky ; S. Purves ; S. Calne ; D. B. Calne | Sinemet in Parkinson's disease: efficacy with and without food |
001193 |
T. A. Larsen ; R. Newman ; P. Lewitt ; D. B. Calne | Severity of Parkinsońs disease and the dosage of bromocriptine |